微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2019, Vol. 11 ›› Issue (4): 313-318.doi: 10.3969/j.issn.1674-5671.2019.04.08

• 临床研究 • 上一篇    下一篇

lncRNA MEG3和lncRNA GAS5在多发性骨髓瘤血清中的表达及其临床意义

  

  1. 吉林省人民医院血液科
  • 出版日期:2019-08-25 发布日期:2019-09-17
  • 通讯作者: 韩梅 E-mail：15843076969@163.com

Expression  of lncRNA MEG3 and lncRNA GAS5 in serum of multiple myeloma and its clinical significance

  • Online:2019-08-25 Published:2019-09-17

PDF (PC)

324

赞

摘要： 目的 探讨长链非编码RNA（long non-coding RNA，lncRNA）母系表达基因3（maternally expressed gene 3，MEG3）和生长特异抑制物5（growth arrest-specific transcript 5，GAS5）在多发性骨髓瘤患者血清中的表达及其与预后的关系。方法 选取本院2014年1月至2016年1月收治的87例多发性骨髓瘤患者为研究对象，同时选取54名健康志愿者为对照。采用实时荧光定量逆转录聚合酶链反应（qRT-PCR）法检测lncRNA MEG3、lncRNA GAS5的表达水平，分析其与多发性骨髓瘤患者临床及预后的关系。结果 多发性骨髓瘤患者血清中lncRNA MEG3和lncRNA GAS5的表达水平均低于对照组（5.92±0.87 vs 9.13±1.26，t=17.882，P<0.001；4.27±0.51 vs 8.26±1.04，t=30.417，P<0.001）。两者表达水平与患者年龄、D-S分期、恶性浆细胞数量、β2-MG水平和血红蛋白含量有关（P＜0.05）。MEG3低表达组和GAS5低表达组的3年总生存率均低于MEG3高表达组和GAS5高表达组（32.56% vs 56.82%，χ2=5.617，P=0.018； 32.43% vs 52.00%，χ2=5.389，P=0.020）。lncRNA MEG3、lncRNA GAS5低表达与多发性骨髓瘤患者不良预后有关（HR=3.503，95%CI：1.517~8.091；HR=3.319，95%CI：1.438~7.661）。结论  lncRNA MEG3和lncRNA GAS5在多发性骨髓瘤患者血清中呈低表达，且与患者不良预后有关。

关键词: 多发性骨髓瘤, 长链非编码RNA, 母系表达基因3, 生长特异抑制物5, 预后

Abstract: Objective To investigate the expression of long non-coding RNA （lncRNA） maternally expressed gene 3 （MEG3） and growth arrest-specific transcript 5（GAS5） in serum of patients with multiple myeloma and their clinical significance. Methods A total of 87 patients with multiple myeloma admitted to our hospital from January 2014 to January 2016 were selected as the study subjects，and 54 healthy volunteers were selected as the control group. The expression levels of lncRNA MEG3 and lncRNA GAS5 were detected by real-time quantitative reverse transcription polymerase chain reaction（qRT-PCR），and their relationships with clinicopathological data and prognosis of patients were analyzed. Results The levels of serum lncRNA MEG3 and lncRNA GAS5 in multiple myeloma patients were lower than those in the control group（5.92±0.87 vs 9.13±1.26，t=17.882，P<0.001；4.27±0.51 vs 8.26±1.04，t=30.417，P<0.001）. The expression levels of them were selected correlated with age，D-S stage，number of malignant plasma cells，β2-MG level and hemoglobin content（P<0.05）. The 3-year overall survival rate of the low-expression group of MEG3 and GAS5 were lower than those of the high-expression group of MEG3 and GAS5（32.56% vs 56.82%，χ2=5.617，P=0.018； 32.43%  vs 52.00%，χ2=5.389，P=0.020）. Low expression of MEG3 and low expression of GAS5 were associated with poor prognosis in patients with multiple myeloma（HR=3.503，95%CI：1.517-8.091；HR=3.319，95%CI：1.438-7.661）. Conclusions lncRNA MEG3 and lncRNA GAS5 are lowly expressed in serum of patients with multiple myeloma，which are related to the poor prognosis of the patients. 

Key words: Multiple myeloma, Long non-coding RNA, Maternally expressed gene 3, Growth arrest-specific transcript 5, Prognosis

中图分类号: 

  • R733.3